Authors: Rudek, MA Figg, WD Dyer, V Dahut, W Turner, ML Steinberg, SM Liewehr, DJ Kohler, DR Pluda, JM Reed, E

Citation: Ma. Rudek et al., Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer, J CL ONCOL, 19(2), 2001, pp. 584-592

Authors: Rudek, MA Horne, M Figg, WD Dahut, W Dyer, V Pluda, JM Reed, E

Citation: Ma. Rudek et al., Reversible sideroblastic anemia associated with the tetracycline analogue COL-3, AM J HEMAT, 67(1), 2001, pp. 51-53

Authors: Carrasquillo, JA Whatley, M Dyer, V Figg, WD Dahut, W

Citation: Ja. Carrasquillo et al., Alendronate does not interfere with Tc-99m-methylene diphosphonate bone scanning, J NUCL MED, 42(9), 2001, pp. 1359-1363

Authors: Ghate, JV Turner, ML Rudek, MA Figg, WD Dahut, W Dyer, V Pluda, JM Reed, E

Citation: Jv. Ghate et al., Drug-induced lupus associated with COL-3 - Report of 3 cases, ARCH DERMAT, 137(4), 2001, pp. 471-474

Authors: Bauer, KS Figg, WD Hamilton, JM Jones, EC Premkumar, A Steinberg, SM Dyer, V Linehan, WM Pluda, JM Reed, E

Citation: Ks. Bauer et al., A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer, CLIN CANC R, 5(9), 1999, pp. 2324-2329